Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NASDAQ Intention to List

20 May 2020 07:00

RNS Number : 4057N
Silence Therapeutics PLC
20 May 2020
 

THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE EU MARKET ABUSE REGULATION (596/2014). UPON THE PUBLICATION OF THE ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN

 

Silence Therapeutics Announces Intent to Submit Registration Statement to the U.S. SEC to Facilitate Nasdaq Listing of ADSs Representing Ordinary Shares

 

20 May 2020

 

LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces it intends to confidentially submit a registration statement to the United States Securities and Exchange Commission (SEC) in connection with a proposed listing of American Depositary Shares (ADSs) representing the Company's ordinary shares on the Nasdaq Stock Market (Nasdaq). The registration statement will be submitted to facilitate the creation of a trading market in the US for ADSs representing the Company's ordinary shares. The Company is not proposing to register any new issuance of securities. The registration statement will be subject to review by the SEC, and the proposed listing of ADSs representing the Company's ordinary shares is subject to approval by Nasdaq. The Company expects that its ordinary shares will continue to be admitted to trading on the AIM market of the London Stock Exchange.

 

 

 

For more information, please contact:

 

Silence Therapeutics plc

Iain Ross, Executive Chairman

Rob Quinn, Chief Financial Officer

 

 

Tel: +44 (0)20 3457 6900

Investec (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

Tel: +44 (0) 20 7597 5970

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

silencetherapeutics@consilium-comms.com

 

Tel: +44 (0) 20 3709 5700

U.S. IR

Westwicke

Peter Vozzo

peter.vozzo@westwicke.com

 Tel: +1 (443) 213-0505

 

 

 

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

 

 

This announcement is being made pursuant to and in accordance with Rule 135 under the Securities Act of 1933, as amended. This announcement does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

 

The person who arranged for the release of this announcement on behalf of the Company was Rob Quinn, Chief Financial Officer.

 

 

Forward Looking Statements

 

Certain statements made in this announcement are forward-looking statements including with respect to the Company's intention to submit a registration statement to the U.S. Securities and Exchange Commission and the creation of a trading market for ADSs representing the Company's ordinary shares in the United States. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements including if the Company's registration statement is not declared effective by the SEC or if Nasdaq fails to approve the Company's ADS listing application. The Company cautions securityholders and prospective securityholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCFLFLAEDIALII
Date   Source Headline
30th Jul 200812:00 pmPRNStatement re Update Regarding Milestone Payment
25th Jul 200810:57 amPRNHolding(s) in Company
24th Jul 20082:00 pmPRNTiming of AGM and Interim Results
24th Jul 20087:00 amPRNHolding(s) in Company
11th Jul 200812:12 pmPRNStatement re Successful Patent Opposition
1st Jul 20087:00 amPRNDirectorate Change
25th Jun 200812:30 pmPRNResearch Update
25th Jun 20087:00 amPRNAnnual Report and Accounts
24th Jun 20083:50 pmPRNHolding(s) in Company
18th Jun 20081:10 pmPRNHolding(s) in Company
9th Jun 20087:00 amRNSPresentations at upcoming con
5th Jun 20087:00 amPRNHolding(s) in Company
16th May 20082:05 pmPRNHolding(s) in Company
6th May 20089:00 amRNSPresentation at Conference
7th Apr 20084:12 pmRNSHolding(s) in Company
7th Apr 20087:01 amRNSDevelopment Concept Supported
1st Apr 20087:05 amPRNDirector/PDMR Shareholding
31st Mar 20087:49 amPRNDirector/PDMR Shareholding
27th Mar 20082:24 pmPRNHolding(s) in Company
27th Mar 20087:00 amPRNPreliminary Final Results
19th Mar 20082:30 pmPRNNotice of Results
19th Mar 200810:56 amPRNHolding(s) in Company
13th Mar 20082:15 pmPRNRe Agreement
13th Mar 200810:54 amPRNHolding(s) in Company
5th Feb 200811:00 amPRNHolding(s) in Company
31st Jan 20084:25 pmPRNHolding(s) in Company
30th Jan 20087:00 amPRNHolding(s) in Company
23rd Jan 200810:05 amPRNHolding(s) in Company
21st Jan 20084:09 pmPRNHolding(s) in Company
17th Jan 20087:00 amPRNHolding(s) in Company
7th Jan 20087:00 amPRNStatement re Chairman's Letter to Shareholders
2nd Jan 20084:25 pmPRNHolding(s) in Company
2nd Jan 200811:10 amPRNHolding(s) in Company
24th Dec 20077:00 amPRNDirector/PDMR Shareholding
17th Dec 20071:40 pmPRNStatement re Share Price Movement
14th Dec 20074:20 pmPRNHolding(s) in Company
12th Dec 20071:31 pmPRNHolding(s) in Company
4th Dec 20074:23 pmPRNHolding(s) in Company
26th Nov 20074:21 pmPRNHolding(s) in Company
23rd Nov 20073:30 pmPRNHolding(s) in Company
20th Nov 20077:00 amPRNChange of Nomad
19th Nov 20071:00 pmPRNResearch Update
19th Nov 20077:02 amRNSPresentation at Conference
5th Nov 20071:20 pmPRNHolding(s) in Company
2nd Nov 200712:35 pmPRNHolding(s) in Company
2nd Nov 20077:01 amRNSConference Attendance
30th Oct 200710:00 amPRNHolding(s) in Company
29th Oct 20074:15 pmPRNHolding(s) in Company
26th Oct 20074:15 pmPRNHolding(s) in Company
25th Oct 200711:10 amPRNHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.